FK Laboratoriz has developed a drug which is a new structure of a highly specific direct thrombin inhibitor. Its expected pharmacological effects correspond to those stipulated by international standards and enable the product to compete with other medicinal products available at the EEU market. The drug was developed with the use of a combination